• Pharmx accelerated revenue growth by 13% in FY2025
• Launched new Supplier and Pharmacy Portals to enhance customer experience
• Signed significant new agreement with Toniq to access nearly all New Zealand pharmacies

Pharmx Technologies Limited has reported its FY2025 annual results, with the company achieving strong revenue growth of 13% compared to the prior year. This growth was driven by new supplier partnerships, including Pave (Thankyou brands), Healthy Life, Homart, and MCo Beauty, as well as strong performance in the Marketplace platform, which saw revenues increase by 193% over FY2024. In addition to the revenue growth, the company made significant strategic investments during the year, including the development and launch of its new Supplier and Pharmacy Portals. The Supplier Portal aims to reduce barriers to entry for suppliers, providing them with near-instant access to 99% of the ANZ pharmacy market. The Pharmacy Portal is a centralized platform designed to streamline operations for pharmacies, offering features such as order and invoice history, real-time spending insights, and seamless account management. The company also made progress in its data analytics business, securing agreements with 13 suppliers. Pharmx's financial results for the year included a profit before tax from continuing operations of $79,000, which was lower than the prior year due to the investment in technology, marketing, and sales resources. The company's cash position at the end of the year was $4,172,000, with a disciplined approach to spending during the second half of the year despite the significant investments. The company also secured a significant new agreement with Toniq, the leading provider of point-of-sale software to the New Zealand market, which is expected to provide a significant revenue opportunity going forward.

Pharmx Technologies Limited expects continued growth in its core Pharmx revenues, driven by an increasing customer base and enhanced engagement with those customers. The company remains committed to investing in innovation, including the development of a unified single platform solution, increased use of AI, and investment in platform automation, digital enablement, and commercial resources to drive efficiency, accelerate supplier onboarding, and expand its addressable market.

The Australian pharmacy market remains highly attractive, driven by population growth, demographic shifts, and regulatory controls, with the AU-NZ retail pharmacy market forecasted to grow at 7.6% CAGR by 2030. Pharmx is well-positioned to capitalize on this growth, with its strategic investments in technology and people aimed at enhancing customer experience, reducing barriers to accessing the Pharmx network, and driving deeper engagement from pharmacies.